WO2021129340A1 - Tandospirone pharmaceutical composition, preparation method therefor and use thereof - Google Patents
Tandospirone pharmaceutical composition, preparation method therefor and use thereof Download PDFInfo
- Publication number
- WO2021129340A1 WO2021129340A1 PCT/CN2020/133624 CN2020133624W WO2021129340A1 WO 2021129340 A1 WO2021129340 A1 WO 2021129340A1 CN 2020133624 W CN2020133624 W CN 2020133624W WO 2021129340 A1 WO2021129340 A1 WO 2021129340A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tandospirone
- optionally
- pharmaceutical composition
- hpmc
- cellulose
- Prior art date
Links
- CEIJFEGBUDEYSX-FZDBZEDMSA-N tandospirone Chemical compound O=C([C@@H]1[C@H]2CC[C@H](C2)[C@@H]1C1=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 CEIJFEGBUDEYSX-FZDBZEDMSA-N 0.000 title claims abstract description 101
- 229950000505 tandospirone Drugs 0.000 title claims abstract description 101
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 67
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 claims abstract description 53
- 239000000463 material Substances 0.000 claims abstract description 27
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 25
- 238000004061 bleaching Methods 0.000 claims abstract description 24
- 239000000945 filler Substances 0.000 claims abstract description 19
- 239000000314 lubricant Substances 0.000 claims abstract description 17
- 239000004480 active ingredient Substances 0.000 claims abstract description 16
- 239000011230 binding agent Substances 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 12
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims abstract description 10
- -1 polyoxyethylene Polymers 0.000 claims abstract description 7
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 claims abstract description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 claims abstract description 5
- 235000017550 sodium carbonate Nutrition 0.000 claims abstract description 5
- 239000012453 solvate Substances 0.000 claims abstract description 5
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims abstract description 3
- 229910000019 calcium carbonate Inorganic materials 0.000 claims abstract description 3
- 235000010216 calcium carbonate Nutrition 0.000 claims abstract description 3
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 claims abstract description 3
- 239000001095 magnesium carbonate Substances 0.000 claims abstract description 3
- 229910000021 magnesium carbonate Inorganic materials 0.000 claims abstract description 3
- 235000014380 magnesium carbonate Nutrition 0.000 claims abstract description 3
- 239000011736 potassium bicarbonate Substances 0.000 claims abstract description 3
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims abstract description 3
- 235000015497 potassium bicarbonate Nutrition 0.000 claims abstract description 3
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims abstract description 3
- 239000008187 granular material Substances 0.000 claims description 28
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 27
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 27
- 239000000203 mixture Substances 0.000 claims description 25
- 239000003826 tablet Substances 0.000 claims description 25
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 17
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 16
- 238000000034 method Methods 0.000 claims description 14
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 10
- 239000011812 mixed powder Substances 0.000 claims description 10
- 238000007873 sieving Methods 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 8
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 7
- 102220487426 Actin-related protein 2/3 complex subunit 3_K15M_mutation Human genes 0.000 claims description 6
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 5
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 5
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 5
- 239000007779 soft material Substances 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 4
- 208000022873 Ocular disease Diseases 0.000 claims description 4
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 4
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 4
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 4
- 208000015114 central nervous system disease Diseases 0.000 claims description 4
- 238000007907 direct compression Methods 0.000 claims description 4
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N lactose group Chemical group OC1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@@H](O)[C@H](O2)CO)[C@H](O1)CO GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 4
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 4
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000001856 Ethyl cellulose Substances 0.000 claims description 3
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 229920002678 cellulose Polymers 0.000 claims description 3
- 239000001913 cellulose Substances 0.000 claims description 3
- 235000010980 cellulose Nutrition 0.000 claims description 3
- 229920002301 cellulose acetate Polymers 0.000 claims description 3
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 3
- 229920001249 ethyl cellulose Polymers 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- 229920000609 methyl cellulose Polymers 0.000 claims description 3
- 239000001923 methylcellulose Substances 0.000 claims description 3
- 235000010981 methylcellulose Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 239000004375 Dextrin Substances 0.000 claims description 2
- 229920001353 Dextrin Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- 229910002651 NO3 Inorganic materials 0.000 claims description 2
- 208000007443 Neurasthenia Diseases 0.000 claims description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 2
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 claims description 2
- 229930006000 Sucrose Natural products 0.000 claims description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- WJEIYVAPNMUNIU-UHFFFAOYSA-N [Na].OC(O)=O Chemical compound [Na].OC(O)=O WJEIYVAPNMUNIU-UHFFFAOYSA-N 0.000 claims description 2
- 239000008186 active pharmaceutical agent Substances 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 230000001070 adhesive effect Effects 0.000 claims description 2
- 206010064930 age-related macular degeneration Diseases 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 206010003549 asthenia Diseases 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 239000001110 calcium chloride Substances 0.000 claims description 2
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 2
- 235000011148 calcium chloride Nutrition 0.000 claims description 2
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims description 2
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium oxide Chemical compound [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 claims description 2
- 239000000292 calcium oxide Substances 0.000 claims description 2
- ODINCKMPIJJUCX-UHFFFAOYSA-N calcium oxide Inorganic materials [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 claims description 2
- 239000008116 calcium stearate Substances 0.000 claims description 2
- 235000013539 calcium stearate Nutrition 0.000 claims description 2
- 235000011132 calcium sulphate Nutrition 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 235000019425 dextrin Nutrition 0.000 claims description 2
- 235000019700 dicalcium phosphate Nutrition 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 229940050411 fumarate Drugs 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 235000001727 glucose Nutrition 0.000 claims description 2
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 239000008101 lactose Substances 0.000 claims description 2
- 208000002780 macular degeneration Diseases 0.000 claims description 2
- 201000010230 macular retinal edema Diseases 0.000 claims description 2
- 229940037627 magnesium lauryl sulfate Drugs 0.000 claims description 2
- 239000000395 magnesium oxide Substances 0.000 claims description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 2
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 claims description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 229910002055 micronized silica Inorganic materials 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 201000000980 schizophrenia Diseases 0.000 claims description 2
- 239000000741 silica gel Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 claims description 2
- 235000011152 sodium sulphate Nutrition 0.000 claims description 2
- OKODKVMXHLUQSW-JITBQSAISA-M sodium;(e)-4-hydroxy-4-oxobut-2-enoate;octadecanoic acid Chemical compound [Na+].OC(=O)\C=C\C([O-])=O.CCCCCCCCCCCCCCCCCC(O)=O OKODKVMXHLUQSW-JITBQSAISA-M 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 239000005720 sucrose Substances 0.000 claims description 2
- 239000000454 talc Substances 0.000 claims description 2
- 229910052623 talc Inorganic materials 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 239000000230 xanthan gum Substances 0.000 claims description 2
- 229920001285 xanthan gum Polymers 0.000 claims description 2
- 235000010493 xanthan gum Nutrition 0.000 claims description 2
- 229940082509 xanthan gum Drugs 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000011787 zinc oxide Substances 0.000 claims description 2
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 2
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 claims 1
- 150000002688 maleic acid derivatives Chemical class 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 41
- 210000002784 stomach Anatomy 0.000 abstract description 8
- 230000014759 maintenance of location Effects 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 20
- 239000008280 blood Substances 0.000 description 10
- 210000004369 blood Anatomy 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000004090 dissolution Methods 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 6
- 239000003405 delayed action preparation Substances 0.000 description 6
- 241000282472 Canis lupus familiaris Species 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 239000007939 sustained release tablet Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000000049 anti-anxiety effect Effects 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 3
- 210000004051 gastric juice Anatomy 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000005923 long-lasting effect Effects 0.000 description 3
- 210000001187 pylorus Anatomy 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000013268 sustained release Methods 0.000 description 3
- 239000012730 sustained-release form Substances 0.000 description 3
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000000147 hypnotic effect Effects 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000011056 performance test Methods 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000001624 sedative effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 235000020927 12-h fasting Nutrition 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010021118 Hypotonia Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 229940125713 antianxiety drug Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000012738 dissolution medium Substances 0.000 description 1
- 238000007922 dissolution test Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 230000030136 gastric emptying Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 239000003326 hypnotic agent Substances 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003715 limbic system Anatomy 0.000 description 1
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 230000036640 muscle relaxation Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000008062 neuronal firing Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 210000001609 raphe nuclei Anatomy 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Definitions
- Tandospirone is a new type of anti-anxiety drug developed by Japan's Sumitomo Pharmaceutical Co., Ltd., and it was approved for listing in Japan in 1996. It entered the Chinese market in 2004 and has become increasingly widely used in the domestic anti-anxiety field. Tandospirone can selectively act on 5-HT 1A receptors in the brain, focusing on the limbic system such as the hippocampus and amygdala of the emotional center and projecting to the raphe nucleus of 5-HTergic nerves, by activating the presynaptic The 5-HT 1A receptor inhibits neuronal firing and reduces the synthesis of 5-HT.
- Tandospirone has specific anti-anxiety effects, fewer side effects, weak sedative and hypnotic effects, no muscle relaxation, no dependence and withdrawal symptoms, and no accumulation in the body after long-term use Such advantages have broad application prospects in the field of anti-anxiety.
- tandospirone is sold as ordinary tablets and capsules in the form of its citrate, and the dosage is 10 mg three times a day.
- the three-times-a-day dosing regimen such as large fluctuations in blood concentration and poor patient compliance with medications.
- the medication compliance problem is particularly obvious.
- a once-a-day sustained-release preparation can not only reduce the peak concentration of the drug in the blood, reduce or avoid dose-related side effects, and increase the efficacy of the drug by prolonging the effective concentration of the drug in the plasma.
- the once-a-day administration improves the convenience of taking the medication, can effectively improve the patient's medication compliance, and reduce the patient's stigma.
- Patent CN1899287A discloses a sustained-release pharmaceutical composition of tandospirone citrate, specifically a sustained-release tablet.
- the matrix material used is hydroxypropyl methylcellulose K4M, which can make the number of administrations change from The three times a day is reduced to twice a day, the frequency of administration is reduced, and the medication is convenient.
- the twice-daily administration method still cannot solve the problem of patient compliance with medication.
- Patent application CN106619481A discloses a sustained-release preparation of tandospirone citrate and a preparation method thereof.
- the preparation contains a certain proportion of tandospirone citrate, a hydrophilic gel material and a waxy material, and Add the right amount of fillers and lubricants.
- the sustained-release preparation has the effect of maintaining the sustained release for 24 hours.
- the inventor further studied its pharmacokinetics and found that the bioavailability of the sustained-release preparation is still not very satisfactory, which affects the therapeutic effect of the drug.
- the present invention aims to provide a tandospirone pharmaceutical composition to solve the problems of frequent medications, poor medication compliance of patients, large fluctuations in blood drug concentration, large drug side effects, low bioavailability and the like.
- the present invention provides a tandospirone pharmaceutical composition, which is characterized in that it comprises a pharmaceutical active ingredient, a matrix material, a filler, a bleaching aid, a lubricant, and an optional binder.
- the ingredient is tandospirone, a pharmaceutically acceptable salt thereof, or a solvate of tandospirone or a pharmaceutically acceptable salt thereof;
- the framework material includes one or a combination of several selected from polyethylene oxide WSR 303, polyethylene oxide WSR 1105, polyethylene oxide WSR 301, polyethylene oxide WSR 205, and polyethylene oxide N-80;
- the bleaching aid is selected from one or a combination of sodium carbonate, sodium bicarbonate, potassium bicarbonate, magnesium carbonate, and calcium carbonate; optionally, the bleaching aid is selected from sodium carbonate and/or carbonic acid Sodium hydrogen.
- the pharmaceutical active ingredient is tandospirone or a pharmaceutically acceptable salt thereof
- the solvate of the tandospirone or a pharmaceutically acceptable salt thereof is in the form of a hydrate.
- the content of the active pharmaceutical ingredient in the tandospirone pharmaceutical composition is 1-15%;
- the content of the pharmaceutical active ingredient in the tandospirone pharmaceutical composition is 2.5-10%, the content of the framework material is 5-75%, and the content of the bleaching aid is 1-20%; optionally,
- the tandospirone pharmaceutical composition includes the following components in weight percentage:
- the tandospirone pharmaceutical composition includes the following components in weight percentage:
- the tandospirone pharmaceutical composition includes the following components in weight percentage:
- the pharmaceutically acceptable salt is hydrochloride, sulfate, tartrate, oxalate, maleate, fumarate, citrate, methanesulfonate, p-toluenesulfonate Acid salt, nitrate; preferably hydrochloride or citrate; more preferably citrate.
- the framework material also optionally includes selected from hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC), methyl cellulose (MC) ), ethyl cellulose (EC), cellulose acetate (CA), cross-linked polyvinylpyrrolidone, croscarmellose sodium, or a combination of several;
- HPC hydroxypropyl cellulose
- HEC hydroxyethyl cellulose
- HPMC hydroxypropyl methyl cellulose
- MC methyl cellulose
- EC ethyl cellulose
- CA cellulose acetate
- cross-linked polyvinylpyrrolidone croscarmellose sodium, or a combination of several
- the hydroxypropyl methylcellulose is selected from one or a combination of HPMC E4M, HPMC E10M, HPMC K4M, HPMC K15M, HPMC K100M;
- the hydroxypropyl methylcellulose is selected from one or a combination of HPMC K4M, HPMC K15M, HPMC K100M;
- the framework material is selected from polyethylene oxide WSR 303, polyethylene oxide WSR 1105, polyethylene oxide WSR 301, polyethylene oxide WSR 205, polyethylene oxide N-80, HPMC K4M, HPMC K15M, hydroxyethyl One or a combination of cellulose, hydroxypropyl cellulose, and cross-linked polyvinylpyrrolidone;
- the binder is selected from one or a combination of polyvinylpyrrolidone, gelatin, xanthan gum, dextrin, polyvinyl alcohol, and carboxymethyl cellulose;
- the adhesive is selected from polyvinylpyrrolidone and/or polyvinyl alcohol.
- the filler is selected from lactose, sucrose, microcrystalline cellulose, pregelatinized starch, mannitol, sorbitol, xylitol, glucose, calcium sulfate, calcium hydrogen phosphate, calcium phosphate, calcium chloride, One or a combination of aluminum chloride, sodium chloride, calcium oxide, zinc oxide, and magnesium oxide; microcrystalline cellulose can be selected.
- the lubricant is selected from talc, micronized silica gel, magnesium stearate, calcium stearate, zinc stearate, sodium fumarate stearate, magnesium lauryl sulfate, dodecane
- talc micronized silica gel
- magnesium stearate calcium stearate
- zinc stearate sodium fumarate stearate
- magnesium lauryl sulfate sodium fumarate stearate
- dodecane One or a combination of sodium sulfate and hydrogenated vegetable oil may be magnesium stearate.
- the tandospirone pharmaceutical composition includes the following components in weight percentage:
- the tandospirone pharmaceutical composition includes the following components in weight percentage:
- the tandospirone pharmaceutical composition includes the following components in weight percentage:
- the tandospirone pharmaceutical composition includes the following components in weight percentage:
- the tandospirone pharmaceutical composition includes the following components in weight percentage:
- the tandospirone pharmaceutical composition includes the following components in weight percentage:
- the dosage form of the tandospirone pharmaceutical composition is selected from a tablet, a pill, or a capsule, and can be a tablet.
- the mixed powder prepared in step b is compressed into tablets to obtain tablets.
- the compression method is direct compression of powder. Or, use the following preparation steps:
- step b Sieve the bleaching aid and lubricant separately, and mix them with the particles in step a to obtain;
- the granules obtained in step b are compressed to obtain tablets.
- preparation method of the above-mentioned tandospirone pharmaceutical composition adopts the following preparation steps:
- a 16.4mm ⁇ 7.9mm punch is used to compress the mixed powder prepared in step b to obtain a tablet.
- the compression method is direct compression of powder.
- step b Pass the bleaching aid and lubricant through a 20-60 mesh sieve, and mix them with the dry granules obtained in step a for 3-10 minutes, to obtain;
- a 16.4mm ⁇ 7.9mm punch is used to compress the granules obtained in step b to obtain tablets.
- the central nervous system disease includes anxiety, depression, insomnia, schizophrenia, age-related memory disorders, neurasthenia, and Alzheimer's;
- the ocular diseases include diseases such as glaucoma, diabetic retinopathy, age-related macular degeneration, and retinal edema.
- the tandospirone pharmaceutical composition of the present invention can quickly float in a simulated gastric juice environment, and the float-off time is not more than 5 seconds, preferably not more than 3 seconds, more preferably not more than 2 seconds; and the bleaching time is greater than 24 hours.
- the tandospirone pharmaceutical composition of the present invention prolongs the residence time of the drug in the stomach, so that the drug can be fully released and absorbed, can last for more than 12 hours of sustained release, and has high bioavailability.
- the uniformity of drug release is good, there is no risk of sudden release, the blood concentration fluctuation after medication is small, the side effects are small, and the safety is high.
- the tandospirone pharmaceutical composition of the present invention has a small initial volume, making the product easy to swallow, and can quickly expand to a diameter of about 14 mm or more in simulated gastric juice, making it difficult to be excreted by gastric contents. Not affected by eating. After the drug is released, it can gradually become smaller and discharged from the pylorus, avoiding the drug from staying in the stomach and reducing the burden on the stomach.
- the tandospirone pharmaceutical composition of the present invention can be taken only once a day, which improves the convenience of taking medication and greatly increases the medication compliance of patients.
- the tandospirone pharmaceutical composition of the invention has stable quality and is suitable for long-term storage and transportation; the preparation process is simple, no special equipment requirements are required, the process controllability is strong, and it is suitable for industrial production.
- the tandospirone pharmaceutical composition was prepared according to the components and proportions shown in Table 1-3.
- step b Use a 16.4mm ⁇ 7.9mm punch to directly compress the mixed powder prepared in step b to obtain tablets.
- step b Pass the bleaching aid through a 20-mesh sieve and mix with the dry granules prepared in step a for 5 minutes; then add magnesium stearate (pass through a 60-mesh sieve) and mix for 3 minutes to obtain mixed granules;
- step b Use a 16.4mm ⁇ 7.9mm punch to compress the mixed granules prepared in step b to obtain tablets.
- Test 1 Floating performance test of Tandospirone pharmaceutical composition
- Example 1 2 3 4 5 6 7 8 9 10 Drift time 4s ⁇ 2s 2s ⁇ 2s ⁇ 2s ⁇ 2s ⁇ 2s ⁇ 2s 4s Drifting time* 24h 24h 24h 24h 24h 24h 24h 24h 24h 24h 24h 24h 24h 24h 24h 24h 24h
- Example 11 12 13 14 15 16 17 18 19 20 Comparative example 1 Drift time ⁇ 2s ⁇ 2s 4s 3s 3s ⁇ 2s ⁇ 2s 5s 4s 5s Unable to float Drifting time* 24h 24h 24h 24h 24h 24h 24h 24h 24h 24h /
- the tandospirone pharmaceutical composition of the present invention has a short bleaching time, which does not exceed 5s, preferably does not exceed 3s, and even more preferably does not exceed 2s.
- the tandospirone pharmaceutical composition of the invention can achieve 24 hours of bleaching.
- the excellent floating performance allows the tandospirone pharmaceutical composition product of the present invention to stay in the stomach for a long time, effectively prolong the release of the drug in the stomach, and enhance the absorption effect of the drug at the absorption site, thereby improving the bioavailability of the drug. To achieve better drug treatment effect.
- the product size of the tandospirone pharmaceutical composition of the present invention swells rapidly in a simulated gastric juice environment, and the smallest diameter can swell to more than 14 mm, which is 13 mm larger than the diameter of the human gastric pylorus. After being placed for 16 hours, the minimum diameter of the product can still be maintained above 13mm.
- the swelling property of the product of the present invention can prolong the residence time of the tandospirone pharmaceutical composition in the stomach, increase the release and absorption of the drug, and achieve the purpose of a lasting, flat and slow-release drug.
- the pharmaceutical composition of the present invention dissolves to a size smaller than the diameter of the gastric pylorus after 24 hours, ensuring the smooth discharge of the drug carrier.
- the first method (basket method) of the dissolution and release determination method in the four appendices of the Chinese Pharmacopoeia 2015 edition was used to investigate the in vitro dissolution conditions of Examples 1-20.
- Table 7-8 The specific results are shown in Table 7-8.
- the investigation conditions are strong light irradiation (4500 ⁇ 500lx), high temperature (60°C), and high humidity (relative humidity 92.5%, 25°C).
- the preparations prepared in Example 6 of the present invention were placed under the above-mentioned different investigation conditions for 10 days respectively, and samples were taken for determination on the 5th and 10th days respectively, and compared with the data of the same batch of samples on day 0. The results are shown in Table 9.
- test results in Table 9 show that the tandospirone pharmaceutical composition of the present invention has no significant changes in product content and total impurities under strong light irradiation, high temperature and high humidity conditions, indicating that the product of the present invention has good stability .
- Example 6 of the present invention The preparation prepared in Example 6 of the present invention was sealed and packaged in a polyethylene film plastic bag, and placed in a constant temperature and humidity incubator at 40°C ⁇ 2°C and a relative humidity of 75 ⁇ 5% for six months. Sampling and testing at the end of 2, 3, and 6 months, and compared with the results of 0 months. The results are shown in Table 10.
- test results in Table 10 show that the tandospirone pharmaceutical composition of the present invention has no significant decrease in content and no significant increase in the total amount of impurities under the accelerated test conditions within six months, which meets the quality standard. It can be seen that the tandospirone pharmaceutical composition provided by the present invention has stable quality and is suitable for long-term storage.
- Tandospirone citrate tablets (commercial preparation, manufacturer: Suzhou Sumitomo Pharmaceutical Co., Ltd., specification: 10mg)
- the LC-MS/MS method was used to determine the concentration of tandospirone in the plasma of Beagle dogs and calculate the relevant pharmacokinetic parameters.
- the AUC 0- ⁇ of the sustained-release preparation was bioequivalence with the 3 times AUC of the normal-release preparation. Inspection, the results are shown in Table 11.
- Tandospirone citrate tablets (commercial preparation, manufacturer: Suzhou Sumitomo Pharmaceutical Co., Ltd., specification: 10mg)
- a randomized, open, three-agent, two-period, sequential, and double-crossover experimental design was adopted, and the cleaning period between the weeks was 4 days.
- the commercial tandospirone citrate tablets are taken three times on the first day of each cycle, with an interval of 5 hours, 10 mg each time; 30 mg of the preparation of the present invention is taken on the second day of each cycle.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Inorganic Chemistry (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
A tandospirone pharmaceutical composition, a preparation method therefor and a use thereof. The tandospirone pharmaceutical composition comprises a pharmaceutical active ingredient, a skeleton material, a filler, a bleaching aid, a lubricant, and an optional binder. The pharmaceutical active ingredient is tandospirone and a pharmaceutically acceptable salt thereof, or tandospirone, or a solvate of the pharmaceutically acceptable salt thereof; the skeleton material comprises one or a combination of multiple selected among polyoxyethylene WSR 303, polyoxyethylene WSR 1105, polyoxyethylene WSR 301, polyoxyethylene WSR 205, and polyoxyethylene N-80; and the bleaching aid is selected from one or a combination of multiple among sodium carbonate, sodium bicarbonate, potassium bicarbonate, magnesium carbonate, and calcium carbonate. The tandospirone pharmaceutical composition prolongs the retention time of a drug in the stomach, such that the drug may be fully released and absorbed, and the bioavailability thereof is greatly improved.
Description
坦度螺酮是由日本住友制药株式会社开发的一种新型抗焦虑药，并于1996年在日本获准上市，2004年开始进入中国市场，在国内抗焦虑领域的应用日益广泛。坦度螺酮能够选择性作用于脑内5-HT
1A受体，作用部位集中在情感中枢的海马、杏仁核等大脑边缘系统并投射至5-HT能神经的中缝核，通过激活突触前5-HT
1A受体，抑制神经元放电，减少5-HT的合成，同时对突触后的5-HT
1A受体具有部分激动作用，从而达到综合调节突触的5-HT功能，发挥抗焦虑作用。长期使用同时还可以发挥抗抑郁作用。与传统镇静催眠药相比，坦度螺酮具有抗焦虑作用专一、副作用较少、镇静催眠作用弱、无肌肉松弛作用、无依赖性和停药戒断症状、长期应用后在体内无蓄积等优势，在抗焦虑领域应用前景广阔。
Tandospirone is a new type of anti-anxiety drug developed by Japan's Sumitomo Pharmaceutical Co., Ltd., and it was approved for listing in Japan in 1996. It entered the Chinese market in 2004 and has become increasingly widely used in the domestic anti-anxiety field. Tandospirone can selectively act on 5-HT 1A receptors in the brain, focusing on the limbic system such as the hippocampus and amygdala of the emotional center and projecting to the raphe nucleus of 5-HTergic nerves, by activating the presynaptic The 5-HT 1A receptor inhibits neuronal firing and reduces the synthesis of 5-HT. At the same time, it has a partial agonistic effect on the 5-HT 1A receptor at the postsynaptic, so as to achieve comprehensive regulation of the synaptic 5-HT function and exert anti- Anxiety effect. Long-term use can also play an anti-depressant effect. Compared with traditional sedative and hypnotics, Tandospirone has specific anti-anxiety effects, fewer side effects, weak sedative and hypnotic effects, no muscle relaxation, no dependence and withdrawal symptoms, and no accumulation in the body after long-term use Such advantages have broad application prospects in the field of anti-anxiety.
目前，临床上坦度螺酮以其枸橼酸盐的形式，作为普通片剂和胶囊剂销售，剂量是一日三次，每次10mg。每日三次的给药方案存在较多问题，如血药浓度波动大，患者服药顺应性差等。尤其对于年长患者和同时服用多种药物的患者而言，服药顺应性问题尤其明显。另外，在精神疾病患者中普遍存在“病耻感”的共性问题，它给患者带来诸多不良影响，其中最为明显的是服药顺应性差，从而导致药物治疗效果不理想。开发每日一次给药的缓释制剂不仅可以降低药物在血液中的药峰浓度，减轻或避免与剂量相关的副作用，并通过延长药物在血浆中的有效浓度而增加药物疗效。同时，每日一次给药提高了服药的便利性，可以有效改善患者的服药顺应性，降低患者病耻感。At present, clinically, tandospirone is sold as ordinary tablets and capsules in the form of its citrate, and the dosage is 10 mg three times a day. There are many problems with the three-times-a-day dosing regimen, such as large fluctuations in blood concentration and poor patient compliance with medications. Especially for elderly patients and patients who take multiple drugs at the same time, the medication compliance problem is particularly obvious. In addition, there is a common problem of "stigma" in patients with mental illness, which brings many adverse effects to patients, the most obvious of which is poor medication compliance, which leads to unsatisfactory drug treatment effects. The development of a once-a-day sustained-release preparation can not only reduce the peak concentration of the drug in the blood, reduce or avoid dose-related side effects, and increase the efficacy of the drug by prolonging the effective concentration of the drug in the plasma. At the same time, the once-a-day administration improves the convenience of taking the medication, can effectively improve the patient's medication compliance, and reduce the patient's stigma.
由于受胃排空和肠道转运的影响，普通缓释制剂在人体上消化道(胃、十二指肠)内的停留时间较短，部分药物尚未完全释放或吸收就 已被转运至下消化道，错失最佳的吸收部位，从而导致部分药物被浪费，影响到药物的治疗效果。Due to the influence of gastric emptying and intestinal transport, the residence time of ordinary sustained-release preparations in the human upper digestive tract (stomach, duodenum) is relatively short, and some drugs have been transported to the lower digestion before they are completely released or absorbed. In this way, the best absorption site is missed, which leads to wasted part of the medicine and affects the therapeutic effect of the medicine.
专利CN1899287A中公开了一种枸橼酸坦度螺酮的缓释药物组合物，具体为一种缓释片，采用的基质材料为羟丙甲基纤维素K4M，其作用可以使给药次数从一天三次减少到一天两次，给药次数减少，服药方便。然而，每日两次的给药方式仍不能很好的解决患者服药顺应性问题。Patent CN1899287A discloses a sustained-release pharmaceutical composition of tandospirone citrate, specifically a sustained-release tablet. The matrix material used is hydroxypropyl methylcellulose K4M, which can make the number of administrations change from The three times a day is reduced to twice a day, the frequency of administration is reduced, and the medication is convenient. However, the twice-daily administration method still cannot solve the problem of patient compliance with medication.
专利申请CN106619481A中公开了一种枸橼酸坦度螺酮的缓释制剂及其制备方法，该制剂包含一定比例的枸橼酸坦度螺酮、亲水性凝胶材料和蜡质材料，并加入适量的填充剂和润滑剂。该缓释制剂具有维持24小时缓释的作用。然而，本发明人进一步研究其药代动力学发现，该缓释制剂的生物利用度仍不十分理想，影响药物的治疗效果。Patent application CN106619481A discloses a sustained-release preparation of tandospirone citrate and a preparation method thereof. The preparation contains a certain proportion of tandospirone citrate, a hydrophilic gel material and a waxy material, and Add the right amount of fillers and lubricants. The sustained-release preparation has the effect of maintaining the sustained release for 24 hours. However, the inventor further studied its pharmacokinetics and found that the bioavailability of the sustained-release preparation is still not very satisfactory, which affects the therapeutic effect of the drug.
发明内容Summary of the invention
本发明旨在提供一种坦度螺酮药物组合物，以解决用药次数多，患者用药顺应性差，血药浓度波动大，药物副作用大，生物利用度低等问题。The present invention aims to provide a tandospirone pharmaceutical composition to solve the problems of frequent medications, poor medication compliance of patients, large fluctuations in blood drug concentration, large drug side effects, low bioavailability and the like.
鉴于此，本发明提供一种坦度螺酮药物组合物，其特征在于，包含药物活性成分、骨架材料、填充剂、助漂剂、润滑剂，以及任选的粘合剂，所述药物活性成分为坦度螺酮、其药学上可接受的盐，或者坦度螺酮或其药学上可接受的盐的溶剂合物；In view of this, the present invention provides a tandospirone pharmaceutical composition, which is characterized in that it comprises a pharmaceutical active ingredient, a matrix material, a filler, a bleaching aid, a lubricant, and an optional binder. The ingredient is tandospirone, a pharmaceutically acceptable salt thereof, or a solvate of tandospirone or a pharmaceutically acceptable salt thereof;
所述骨架材料包括选自聚氧化乙烯WSR 303、聚氧化乙烯WSR 1105、聚氧化乙烯WSR 301、聚氧化乙烯WSR 205、聚氧化乙烯N-80中的一种或几种的组合；The framework material includes one or a combination of several selected from polyethylene oxide WSR 303, polyethylene oxide WSR 1105, polyethylene oxide WSR 301, polyethylene oxide WSR 205, and polyethylene oxide N-80;
所述助漂剂选自碳酸钠、碳酸氢钠、碳酸氢钾、碳酸镁、碳酸钙中的一种或几种的组合；可选地，所述助漂剂选自碳酸钠和/或碳酸氢钠。The bleaching aid is selected from one or a combination of sodium carbonate, sodium bicarbonate, potassium bicarbonate, magnesium carbonate, and calcium carbonate; optionally, the bleaching aid is selected from sodium carbonate and/or carbonic acid Sodium hydrogen.
可选地，所述药物活性成分为坦度螺酮或其药学上可接受的盐；Optionally, the pharmaceutical active ingredient is tandospirone or a pharmaceutically acceptable salt thereof;
可选地，所述坦度螺酮或其药学上可接受的盐的溶剂合物为其水合物的形式。Optionally, the solvate of the tandospirone or a pharmaceutically acceptable salt thereof is in the form of a hydrate.
可选地，所述坦度螺酮药物组合物中药物活性成分的含量为1-15％；Optionally, the content of the active pharmaceutical ingredient in the tandospirone pharmaceutical composition is 1-15%;
可选地，所述坦度螺酮药物组合物中药物活性成分的含量为2.5-10％，骨架材料的含量为5-75％，助漂剂的含量为1-20％；可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the content of the pharmaceutical active ingredient in the tandospirone pharmaceutical composition is 2.5-10%, the content of the framework material is 5-75%, and the content of the bleaching aid is 1-20%; optionally, The tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述药学上可接受的盐为盐酸盐、硫酸盐、酒石酸盐、草酸盐、马来酸盐、富马酸盐、枸橼酸盐、甲磺酸盐、对甲苯磺酸盐、硝酸盐；优选为盐酸盐或枸橼酸盐；更优选为枸橼酸盐。Optionally, the pharmaceutically acceptable salt is hydrochloride, sulfate, tartrate, oxalate, maleate, fumarate, citrate, methanesulfonate, p-toluenesulfonate Acid salt, nitrate; preferably hydrochloride or citrate; more preferably citrate.
可选地，所述骨架材料还任选的包括选自羟丙基纤维素(HPC)、羟乙基纤维素(HEC)、羟丙基甲基纤维素(HPMC)、甲基纤维素(MC)、乙基纤维素(EC)、乙酸纤维素(CA)、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠中的一种或几种的组合；Optionally, the framework material also optionally includes selected from hydroxypropyl cellulose (HPC), hydroxyethyl cellulose (HEC), hydroxypropyl methyl cellulose (HPMC), methyl cellulose (MC) ), ethyl cellulose (EC), cellulose acetate (CA), cross-linked polyvinylpyrrolidone, croscarmellose sodium, or a combination of several;
可选地，所述羟丙基甲基纤维素选自HPMC E4M、HPMC E10M、HPMC K4M、HPMC K15M、HPMC K100M中的一种或几种的组合；Optionally, the hydroxypropyl methylcellulose is selected from one or a combination of HPMC E4M, HPMC E10M, HPMC K4M, HPMC K15M, HPMC K100M;
可选地，所述羟丙基甲基纤维素选自HPMC K4M、HPMC K15M、HPMC K100M中的一种或几种的组合；Optionally, the hydroxypropyl methylcellulose is selected from one or a combination of HPMC K4M, HPMC K15M, HPMC K100M;
可选地，所述骨架材料选自聚氧化乙烯WSR 303、聚氧化乙烯WSR 1105、聚氧化乙烯WSR 301、聚氧化乙烯WSR 205、聚氧化乙烯N-80、HPMC K4M、HPMC K15M、羟乙基纤维素、羟丙基纤维素、交联聚乙烯吡咯烷酮中的一种或几种的组合；Optionally, the framework material is selected from polyethylene oxide WSR 303, polyethylene oxide WSR 1105, polyethylene oxide WSR 301, polyethylene oxide WSR 205, polyethylene oxide N-80, HPMC K4M, HPMC K15M, hydroxyethyl One or a combination of cellulose, hydroxypropyl cellulose, and cross-linked polyvinylpyrrolidone;
可选地，所述粘合剂选自聚乙烯吡咯烷酮、明胶、黄原胶、糊精、聚乙烯醇、羧甲基纤维素中的一种或几种的组合；Optionally, the binder is selected from one or a combination of polyvinylpyrrolidone, gelatin, xanthan gum, dextrin, polyvinyl alcohol, and carboxymethyl cellulose;
可选地，所述粘合剂选自聚乙烯吡咯烷酮和/或聚乙烯醇。Optionally, the adhesive is selected from polyvinylpyrrolidone and/or polyvinyl alcohol.
可选地，所述填充剂选自乳糖、蔗糖、微晶纤维素、预胶化淀粉、 甘露醇、山梨醇、木糖醇、葡萄糖、硫酸钙、磷酸氢钙、磷酸钙、氯化钙、氯化铝、氯化钠、氧化钙、氧化锌、氧化镁中的一种或几种的组合；可选为微晶纤维素。Optionally, the filler is selected from lactose, sucrose, microcrystalline cellulose, pregelatinized starch, mannitol, sorbitol, xylitol, glucose, calcium sulfate, calcium hydrogen phosphate, calcium phosphate, calcium chloride, One or a combination of aluminum chloride, sodium chloride, calcium oxide, zinc oxide, and magnesium oxide; microcrystalline cellulose can be selected.
可选地，所述的润滑剂选自滑石粉、微粉硅胶、硬脂酸镁、硬脂酸钙、硬脂酸锌、硬脂酸富马酸钠、十二烷基硫酸镁、十二烷基硫酸钠、氢化植物油中的一种或几种的组合，可选为硬脂酸镁。Optionally, the lubricant is selected from talc, micronized silica gel, magnesium stearate, calcium stearate, zinc stearate, sodium fumarate stearate, magnesium lauryl sulfate, dodecane One or a combination of sodium sulfate and hydrogenated vegetable oil may be magnesium stearate.
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物的剂型选自片剂、丸剂或胶囊，可选为片剂。Optionally, the dosage form of the tandospirone pharmaceutical composition is selected from a tablet, a pill, or a capsule, and can be a tablet.
另一方面，提供一种上述坦度螺酮药物组合物的制备方法，采用以下制备步骤：On the other hand, a method for preparing the above-mentioned tandospirone pharmaceutical composition is provided, which adopts the following preparation steps:
a、将各组分分别过筛，取药物活性成分、骨架材料、粘合剂和填充剂，混合均匀；a. Sieving each component separately, take the active ingredient of the medicine, the skeleton material, the binder and the filler, and mix them evenly;
b、再加入助漂剂、润滑剂混合均匀，制成混合粉末，即得；b. Add bleaching aids and lubricants and mix evenly to make a mixed powder, which is ready;
可选地，将步骤b中制得的混合粉末压片，制得片剂。Optionally, the mixed powder prepared in step b is compressed into tablets to obtain tablets.
可选地，所述压片的方式为粉末直接压片。或者，采用以下制备步骤：Optionally, the compression method is direct compression of powder. Or, use the following preparation steps:
a、将药物活性成分、骨架材料、粘合剂和填充剂分别过筛，混合均匀，加入水制备软材，湿颗粒干燥，整粒过筛，制得干燥颗粒；a. Sieving the active ingredients of the medicine, the framework material, the binder and the filler separately, mixing them evenly, adding water to prepare the soft material, drying the wet granules, sieving the whole granules and sieving them to obtain dry granules;
b、将助漂剂和润滑剂分别过筛，与步骤a中颗粒混合均匀，即得；b. Sieve the bleaching aid and lubricant separately, and mix them with the particles in step a to obtain;
可选地，将步骤b中制得的颗粒进行压片，制得片剂。Optionally, the granules obtained in step b are compressed to obtain tablets.
进一步地，上述坦度螺酮药物组合物的制备方法，采用以下制备步骤：Further, the preparation method of the above-mentioned tandospirone pharmaceutical composition adopts the following preparation steps:
a、将各组分分别过20～60目筛，取药物活性成分、骨架材料、粘合剂和填充剂，混合10～30分钟；a. Pass each component through a 20-60 mesh sieve, take the active ingredient of the medicine, the skeleton material, the binder and the filler, and mix for 10-30 minutes;
b、再依次加入助漂剂、润滑剂混合3～10分钟，制成混合粉末，即得；b. Add bleaching aids and lubricants in sequence and mix for 3-10 minutes to make a mixed powder, ready to be obtained;
可选地，使用16.4mm×7.9mm的冲头将步骤b中制得的混合粉末压片，制得片剂。Optionally, a 16.4mm×7.9mm punch is used to compress the mixed powder prepared in step b to obtain a tablet.
可选地，所述压片的方式为粉末直接压片。Optionally, the compression method is direct compression of powder.
或者，采用以下制备步骤：Or, use the following preparation steps:
a、将药物活性成分、骨架材料、粘合剂和填充剂分别过20～60 目筛，混合5～30分钟，加入水制备软材，湿颗粒在35～70℃、20～50cfm条件下干燥5～30分钟，整粒过10～30目筛，制得干燥颗粒；a. Pass the active ingredients of the medicine, the framework material, the binder and the filler through a 20-60 mesh sieve, mix for 5-30 minutes, add water to prepare a soft material, and dry the wet granules at 35-70℃ and 20-50cfm. After 5-30 minutes, the whole granules are passed through a 10-30 mesh sieve to obtain dry granules;
b、将助漂剂和润滑剂分别过20～60目筛，与步骤a中制得的干燥颗粒混合3～10分钟，即得；b. Pass the bleaching aid and lubricant through a 20-60 mesh sieve, and mix them with the dry granules obtained in step a for 3-10 minutes, to obtain;
可选地，使用16.4mm×7.9mm的冲头将步骤b中制得的颗粒进行压片，制得片剂。Optionally, a 16.4mm×7.9mm punch is used to compress the granules obtained in step b to obtain tablets.
另一方面，提供上述坦度螺酮药物组合物在制备治疗中枢神经系统疾病和眼部疾病的药物中的用途。On the other hand, there is provided the use of the above-mentioned tandospirone pharmaceutical composition in the preparation of a medicine for treating central nervous system diseases and ocular diseases.
可选地，所述中枢神经系统疾病包括焦虑症、抑郁症、失眠症、精神分裂、增龄性记忆障碍、神经衰弱、老年痴呆；Optionally, the central nervous system disease includes anxiety, depression, insomnia, schizophrenia, age-related memory disorders, neurasthenia, and Alzheimer's;
可选地，所述眼部疾病包括青光眼、糖尿病性视网膜病、年龄相关性黄斑变性、视网膜水肿等疾病。Optionally, the ocular diseases include diseases such as glaucoma, diabetic retinopathy, age-related macular degeneration, and retinal edema.
有益技术效果Beneficial technical effect
本发明坦度螺酮药物组合物在模拟胃液环境中，能迅速起漂，起漂时间不超过5秒，优选不超过3秒，更优选不超过2秒；持漂时间大于24小时。The tandospirone pharmaceutical composition of the present invention can quickly float in a simulated gastric juice environment, and the float-off time is not more than 5 seconds, preferably not more than 3 seconds, more preferably not more than 2 seconds; and the bleaching time is greater than 24 hours.
本发明坦度螺酮药物组合物延长了药物在胃中的滞留时间，使得药物可以被充分释放和吸收，可以持续12小时以上的缓释作用，生物利用度高。释药均匀性好，无突释风险，用药后血药浓度波动小，副作用小，安全性高。The tandospirone pharmaceutical composition of the present invention prolongs the residence time of the drug in the stomach, so that the drug can be fully released and absorbed, can last for more than 12 hours of sustained release, and has high bioavailability. The uniformity of drug release is good, there is no risk of sudden release, the blood concentration fluctuation after medication is small, the side effects are small, and the safety is high.
此外，本发明坦度螺酮药物组合物具有较小的初始体积，使得产品易吞服，在模拟胃液中能够迅速膨胀至直径约14mm或更大，使得其不易被胃内容物排走，达到不受进食的影响。药物释放完后能够逐渐溶蚀变小并从幽门排出，避免了药物一直在胃中停留，减轻胃部负担。In addition, the tandospirone pharmaceutical composition of the present invention has a small initial volume, making the product easy to swallow, and can quickly expand to a diameter of about 14 mm or more in simulated gastric juice, making it difficult to be excreted by gastric contents. Not affected by eating. After the drug is released, it can gradually become smaller and discharged from the pylorus, avoiding the drug from staying in the stomach and reducing the burden on the stomach.
本发明坦度螺酮药物组合物每日可只需服药一次，提高了服药便利性，大大增加了患者的用药顺应性。The tandospirone pharmaceutical composition of the present invention can be taken only once a day, which improves the convenience of taking medication and greatly increases the medication compliance of patients.
本发明坦度螺酮药物组合物质量稳定，适合长期储存和运输；制备工艺简单，无特殊设备要求，工艺可操控性强，适合工业化生产。The tandospirone pharmaceutical composition of the invention has stable quality and is suitable for long-term storage and transportation; the preparation process is simple, no special equipment requirements are required, the process controllability is strong, and it is suitable for industrial production.
以下通过具体实施方式对本发明作进一步的详细描述。应当理解的是，此处所描述的具体实施方式仅用于说明和解释本发明，并不用于限制本发明。Hereinafter, the present invention will be further described in detail through specific embodiments. It should be understood that the specific embodiments described here are only used to illustrate and explain the present invention, and are not used to limit the present invention.
实施例1-20Example 1-20
按照表1-3所示的组分和配比来制备坦度螺酮药物组合物。The tandospirone pharmaceutical composition was prepared according to the components and proportions shown in Table 1-3.
表1.坦度螺酮药物组合物—实施例1-8Table 1. Tandospirone pharmaceutical composition-Examples 1-8
表2.坦度螺酮药物组合物—实施例9-14Table 2. Tandospirone pharmaceutical composition-Examples 9-14
表3.坦度螺酮药物组合物—实施例15-20Table 3. Tandospirone pharmaceutical composition-Examples 15-20
对于实施例1-7，9-12以及15-18，其制备工艺如下：For Examples 1-7, 9-12 and 15-18, the preparation process is as follows:
a、将硬脂酸镁过60目筛，除硬脂酸镁以外的各组分分别过20目筛，取枸橼酸坦度螺酮、骨架材料、粘合剂和填充剂，混合15分钟；a. Pass the magnesium stearate through a 60-mesh sieve, and each component except magnesium stearate through a 20-mesh sieve, take the tandospirone citrate, the framework material, the binder and the filler, and mix for 15 minutes ；
b、加入助漂剂，混合10分钟；再加入硬脂酸镁，混合3分钟，制得混合粉末；b. Add bleaching aid and mix for 10 minutes; then add magnesium stearate and mix for 3 minutes to obtain mixed powder;
c、使用16.4mm×7.9mm的冲头将步骤b中制得的混合粉末直接压片，制得片剂。c. Use a 16.4mm×7.9mm punch to directly compress the mixed powder prepared in step b to obtain tablets.
对于实施例8，13-14以及19-20，其制备工艺如下：For Examples 8, 13-14 and 19-20, the preparation process is as follows:
a、将枸橼酸坦度螺酮、骨架材料、粘合剂和填充剂分别过20目筛，混合10分钟；加入水制备软材，湿颗粒于50℃和35cfm条件下干燥15分钟，整粒过20目筛，制得干燥颗粒；a. Pass the tandospirone citrate, the framework material, the binder and the filler through a 20-mesh sieve and mix for 10 minutes; add water to prepare a soft material, and dry the wet granules at 50°C and 35cfm for 15 minutes. The granules are passed through a 20-mesh sieve to obtain dry granules;
b、将助漂剂过20目筛，与步骤a中制得的干燥颗粒混合5分钟；再加入硬脂酸镁(过60目筛)混合3分钟，制得混合颗粒；b. Pass the bleaching aid through a 20-mesh sieve and mix with the dry granules prepared in step a for 5 minutes; then add magnesium stearate (pass through a 60-mesh sieve) and mix for 3 minutes to obtain mixed granules;
c、使用16.4mm×7.9mm的冲头将步骤b中制得的混合颗粒压片， 制得片剂。c. Use a 16.4mm×7.9mm punch to compress the mixed granules prepared in step b to obtain tablets.
对比例1(参照专利申请CN106619481A中实施例1)Comparative example 1 (refer to Example 1 in patent application CN106619481A)
原料处方：Ingredients prescription:
共制成1000片；A total of 1000 pieces;
制备方法：Preparation:
将蜡质材料加热熔融，加入枸橼酸坦度螺酮，搅拌混合均匀，冷却成固态，将含药固体研磨粉碎，过筛，加入亲水性凝胶材料、填充剂、75％乙醇进行制粒，干燥，过筛整粒，加入润滑剂后混合均匀，压片即得。Heat and melt the waxy material, add tandospirone citrate, stir and mix evenly, cool to a solid, grind and crush the medicated solid, sieving, add hydrophilic gel material, filler, and 75% ethanol to prepare Granulate, dry, sieved and granulate, add lubricant and mix evenly, and then it is obtained by pressing.
将蜡质材料加热熔融，加入枸橼酸坦度螺酮，搅拌混合均匀，冷却成固态，将含药固体研磨粉碎，过筛，加入亲水性凝胶材料、填充剂、75％乙醇进行制粒，干燥，过筛整粒，加入润滑剂后混合均匀，压片即得。Heat and melt the waxy material, add tandospirone citrate, stir and mix evenly, cool to a solid, grind and crush the medicated solid, sieving, add hydrophilic gel material, filler, and 75% ethanol to prepare Granulate, dry, sieved and granulate, add lubricant and mix evenly, and then it is obtained by pressing.
试验一坦度螺酮药物组合物漂浮性能试验Test 1: Floating performance test of Tandospirone pharmaceutical composition
试验方法：experiment method:
将实施例1-20以及对比例1制得的片剂置于(37±0.5)℃，900mL 0.1mol/L的盐酸溶液中，搅拌速度为50r/min，观察起漂时间及持漂 时间。具体结果见表4-5。The tablets prepared in Examples 1-20 and Comparative Example 1 were placed in a 900 mL 0.1 mol/L hydrochloric acid solution at (37±0.5)°C at a stirring speed of 50 r/min, and the bleaching time and holding time were observed. The specific results are shown in Table 4-5.
表4坦度螺酮药物组合物漂浮性能—实施例1-10Table 4 Floating performance of Tandospirone pharmaceutical composition-Examples 1-10
| 实施例Example | 11 | 22 | 33 | 44 | 55 | 66 | 77 | 88 | 99 | 1010 |
| 起漂时间Drift time | 4s4s | <2s<2s | 2s2s | <2s<2s | <2s<2s | <2s<2s | <2s<2s | <2s<2s | <2s<2s | 4s4s |
| 持漂时间*Drifting time* | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h |
*注：持漂时间只记录到24h。*Note: The drift time is only recorded up to 24h.
表5坦度螺酮药物组合物漂浮性能—实施例11-20Table 5 Floating performance of Tandospirone pharmaceutical composition-Examples 11-20
| 实施例Example | 1111 | 1212 | 1313 | 1414 | 1515 | 1616 | 1717 | 1818 | 1919 | 2020 | 对比例1Comparative example 1 |
| 起漂时间Drift time | <2s<2s | <2s<2s | 4s4s | 3s3s | 3s3s | <2s<2s | <2s<2s | 5s5s | 4s4s | 5s5s | 无法起漂Unable to float |
| 持漂时间*Drifting time* | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | 24h24h | // |
*注：持漂时间只记录到24h。*Note: The drift time is only recorded up to 24h.
表4-5结果可知，本发明坦度螺酮药物组合物起漂时间短，起漂时间不超过5s，较优的不超过3s，更优的不超过2s。本发明坦度螺酮药物组合物能达到24小时持漂。优良的漂浮性能使得本发明坦度螺酮药物组合物产品在胃中可以滞留较长时间，有效延长药物在胃部的释放，增强药物在吸收部位的吸收效果，从而提高药物的生物利用度，达到更好的药物治疗效果。The results in Table 4-5 show that the tandospirone pharmaceutical composition of the present invention has a short bleaching time, which does not exceed 5s, preferably does not exceed 3s, and even more preferably does not exceed 2s. The tandospirone pharmaceutical composition of the invention can achieve 24 hours of bleaching. The excellent floating performance allows the tandospirone pharmaceutical composition product of the present invention to stay in the stomach for a long time, effectively prolong the release of the drug in the stomach, and enhance the absorption effect of the drug at the absorption site, thereby improving the bioavailability of the drug. To achieve better drug treatment effect.
试验二坦度螺酮药物组合物溶胀性能测定试验Test for the determination of the swelling performance of the two tandospirone pharmaceutical composition
试验方法：experiment method:
将实施例2、6、12中制得的制剂分别置于(37±0.5)℃，900mL 0.1mol/L的盐酸溶液中，测量其在第5min、30min、2h、6h、12h、16h、18h、20h和24h的尺寸，结果见表6。The preparations prepared in Examples 2, 6, and 12 were respectively placed in (37±0.5) ℃, 900mL 0.1mol/L hydrochloric acid solution, and measured at 5min, 30min, 2h, 6h, 12h, 16h, 18h , 20h and 24h size, the results are shown in Table 6.
表6坦度螺酮药物组合物溶胀性能试验结果Table 6 Swelling performance test results of Tandospirone pharmaceutical composition
由表6可知，本发明的坦度螺酮药物组合物在模拟胃液环境下，产品尺寸迅速溶胀，最小直径可溶胀至14mm以上，大于人体胃幽门直径13mm。在放置16小时后，产品最小直径仍能维持在13mm以上。本发明产品的溶胀性能可延长坦度螺酮药物组合物在胃中的滞留时间，增加药物的释放和吸收，达到持久平缓释药的目的。此外，本发明药物组合物在24小时后，产品溶蚀至尺寸小于胃幽门直径，保证了药物载体的顺利排出。It can be seen from Table 6 that the product size of the tandospirone pharmaceutical composition of the present invention swells rapidly in a simulated gastric juice environment, and the smallest diameter can swell to more than 14 mm, which is 13 mm larger than the diameter of the human gastric pylorus. After being placed for 16 hours, the minimum diameter of the product can still be maintained above 13mm. The swelling property of the product of the present invention can prolong the residence time of the tandospirone pharmaceutical composition in the stomach, increase the release and absorption of the drug, and achieve the purpose of a lasting, flat and slow-release drug. In addition, the pharmaceutical composition of the present invention dissolves to a size smaller than the diameter of the gastric pylorus after 24 hours, ensuring the smooth discharge of the drug carrier.
试验三坦度螺酮药物组合物体外溶出度试验In vitro dissolution test of tritandospirone drug combination
采用中国药典2015版四部附录溶出度与释放度测定法第一法(篮法)，考察实施例1-20的体外溶出情况。以900mL 0.1mol/L的盐酸溶液为溶出介质，设置转速为50r/min，温度为37±0.5℃；依法操作，在15min、30min、1h、2h、4h、6h、8h、10h、12h、14h、16h、20h分别取溶液5mL进行测定，并计算出累计溶出度。具体结果见表7-8。The first method (basket method) of the dissolution and release determination method in the four appendices of the Chinese Pharmacopoeia 2015 edition was used to investigate the in vitro dissolution conditions of Examples 1-20. Take 900mL 0.1mol/L hydrochloric acid solution as the dissolution medium, set the speed to 50r/min, and the temperature to 37±0.5℃; operate according to law, 15min, 30min, 1h, 2h, 4h, 6h, 8h, 10h, 12h, 14h , 16h, 20h, respectively, take 5mL of the solution for determination, and calculate the cumulative dissolution rate. The specific results are shown in Table 7-8.
表7实施例1-10的体外溶出结果Table 7 In vitro dissolution results of Examples 1-10
表8实施例11-20的体外溶出结果Table 8 In vitro dissolution results of Examples 11-20
表7-8体外溶出结果表明，实施例1～18的坦度螺酮药物组合物16h溶出度达80％以上，达到持久缓慢释药的目的，且释药平稳，无突释效应，避免了血药浓度大幅度波动。The results of in vitro dissolution in Table 7-8 show that the dissolution rate of the tandospirone pharmaceutical composition of Examples 1 to 18 reached more than 80% in 16 hours, achieving the purpose of long-lasting and slow drug release, and the drug release was stable, without sudden release effect, and avoided The blood drug concentration fluctuates drastically.
试验四坦度螺酮药物组合物稳定性试验Stability test of the drug composition of Sitandospirone
(1)影响因素试验(1) Influencing factor test
考察条件为强光照射(4500±500lx)、高温(60℃)、高湿(相对湿度92.5％，25℃)。将本发明实施例6制备得到的制剂在上述不同考察条件下分别放置10天，于第5和第10天分别取样测定，与0天同批样品数据进行比较，结果见表9。The investigation conditions are strong light irradiation (4500±500lx), high temperature (60°C), and high humidity (relative humidity 92.5%, 25°C). The preparations prepared in Example 6 of the present invention were placed under the above-mentioned different investigation conditions for 10 days respectively, and samples were taken for determination on the 5th and 10th days respectively, and compared with the data of the same batch of samples on day 0. The results are shown in Table 9.
表9影响因素试验结果Table 9 Test results of influencing factors
由表9中的试验结果表明，本发明的坦度螺酮药物组合物，在强光照射、高温及高湿条件下，产品含量和杂质总量均无明显变化，说明本发明产品稳定性良好。The test results in Table 9 show that the tandospirone pharmaceutical composition of the present invention has no significant changes in product content and total impurities under strong light irradiation, high temperature and high humidity conditions, indicating that the product of the present invention has good stability .
(2)加速试验(2) Accelerated test
将本发明实施例6制备得到的制剂用聚乙烯薄膜塑料袋密封包装，置于40℃±2℃，相对湿度75±5％的恒温恒湿培养箱中，放置六个月，分别于1，2，3，6个月末取样检测，并与0月的结果进行对照。结果见表10。The preparation prepared in Example 6 of the present invention was sealed and packaged in a polyethylene film plastic bag, and placed in a constant temperature and humidity incubator at 40°C ± 2°C and a relative humidity of 75 ± 5% for six months. Sampling and testing at the end of 2, 3, and 6 months, and compared with the results of 0 months. The results are shown in Table 10.
表10加速试验结果Table 10 Accelerated test results
由表10中的试验结果表明，本发明坦度螺酮药物组合物，在六个月内的加速试验条件下，含量无明显降低，杂质总量未见明显增加，符合质量标准。由此可见，本发明提供的坦度螺酮药物组合物质量稳定，适宜长期保存。The test results in Table 10 show that the tandospirone pharmaceutical composition of the present invention has no significant decrease in content and no significant increase in the total amount of impurities under the accelerated test conditions within six months, which meets the quality standard. It can be seen that the tandospirone pharmaceutical composition provided by the present invention has stable quality and is suitable for long-term storage.
试验五坦度螺酮药物组合物的药代动力学试验Test the pharmacokinetic test of Wutanduspirone pharmaceutical composition
(一)动物药代动力学试验(1) Animal pharmacokinetic test
试验样品：Test sample:
(1)枸橼酸坦度螺酮片(市售制剂，生产商：苏州住友制药有限公司，规格：10mg)(1) Tandospirone citrate tablets (commercial preparation, manufacturer: Suzhou Sumitomo Pharmaceutical Co., Ltd., specification: 10mg)
(2)枸橼酸坦度螺酮缓释片(对比例1)(2) Tandospirone citrate sustained-release tablets (Comparative Example 1)
(3)本发明制剂(实施例7)(3) Preparation of the present invention (Example 7)
试验方法及试验结果：Test methods and test results:
6只雄性Beagle犬，按体重随机分为3个组，采用3周期、3交叉(3×3拉丁方)设计，每个周期分别经口给予市售枸橼酸坦度螺酮片10mg、对比例1枸橼酸坦度螺酮缓释片30mg、本发明实施例7制剂30mg，给药前禁食12h。给予对比例1枸橼酸坦度螺酮缓释片和本发明实施例7制剂的Beagle犬于每次给药前及给药后0.5min、1h、2h、3h、4h、5h、6h、8h、10h、12h、14h、16h、20h、24h、30h采集血样，给予市售枸橼酸坦度螺酮片的Beagle犬于每次给药前及给药后5min、10min、20min、30min、40min、1h、1.5h、2h、2.5h、 3h、4h、6h、8h、10h、12h采集血样。6 male Beagle dogs were randomly divided into 3 groups according to their body weights, using a 3-cycle, 3-crossing (3×3 Latin square) design, and each cycle was orally given 10mg of commercially available tandospirone citrate tablets, Ratio 1 Tandospirone citrate sustained-release tablets 30mg, the preparation of Example 7 of the present invention 30mg, fasting for 12h before administration. Beagle dogs administered with comparative example 1 tandospirone citrate sustained-release tablets and the preparation of Example 7 of the present invention before each administration and 0.5min, 1h, 2h, 3h, 4h, 5h, 6h, 8h after administration Blood samples were collected at 10h, 12h, 14h, 16h, 20h, 24h, 30h, and Beagle dogs were given commercially available tandospirone citrate tablets before each administration and 5min, 10min, 20min, 30min, 40min after administration , 1h, 1.5h, 2h, 2.5h, 3h, 4h, 6h, 8h, 10h, 12h to collect blood samples.
以LC-MS/MS法测定Beagle犬血浆中坦度螺酮的浓度并计算相关的药代动力学参数，对缓释制剂的AUC
0-∞与常释制剂的3倍AUC进行生物等效性检验，结果见表11。
The LC-MS/MS method was used to determine the concentration of tandospirone in the plasma of Beagle dogs and calculate the relevant pharmacokinetic parameters. The AUC 0-∞ of the sustained-release preparation was bioequivalence with the 3 times AUC of the normal-release preparation. Inspection, the results are shown in Table 11.
表11 Beagle犬药代动力学试验结果Table 11 Beagle dog pharmacokinetic test results
表11结果表明，相较于市售枸橼酸坦度螺酮片，本发明坦度螺酮药物组合物有效延迟了药物的达峰时间(T
max)，降低了峰浓度(C
max)，达到了使枸橼酸坦度螺酮持久平缓释放的目的，且用药安全性得到了保障。与对比例1枸橼酸坦度螺酮缓释片相比，本发明坦度螺酮药物组合物的生物利用度(AUC
0-∞)明显增高，有效提高了生物利用度。
The results in Table 11 show that, compared with the commercially available tandospirone citrate tablets, the tandospirone pharmaceutical composition of the present invention effectively delays the peak time (T max ) of the drug and reduces the peak concentration (C max ). The purpose of long-lasting and gentle release of tandospirone citrate is achieved, and the safety of medication is guaranteed. Compared with the tandospirone citrate sustained-release tablet of Comparative Example 1, the bioavailability (AUC 0-∞ ) of the tandospirone pharmaceutical composition of the present invention is significantly increased, and the bioavailability is effectively improved.
(二)人体药代动力学试验(2) Human pharmacokinetic test
试验样品：Test sample:
(1)枸橼酸坦度螺酮片(市售制剂，生产商：苏州住友制药有限公司，规格：10mg)(1) Tandospirone citrate tablets (commercial preparation, manufacturer: Suzhou Sumitomo Pharmaceutical Co., Ltd., specification: 10mg)
(2)本发明制剂(实施例6)(2) Preparation of the present invention (Example 6)
(3)本发明制剂(实施例7)(3) Preparation of the present invention (Example 7)
试验方法及试验结果：Test methods and test results:
采用随机、开放、三制剂、两周期、序贯、双交叉试验设计，周期间的清洗期为4天。每周期第1天三次服用市售枸橼酸坦度螺酮片，给药间隔5h，每次10mg；每周期第2天服用本发明制剂30mg。每周期第1天受试者于首次给药前(0h)及给药后0.25h、0.5h、1h、1.5h、2h、5h、5.25h、5.5h、6h、6.5h、7h、8h、10h、10.25h、10.5h、11h、11.5h、12h、13h、16h分别采集静脉血3mL，共21个采血点。A randomized, open, three-agent, two-period, sequential, and double-crossover experimental design was adopted, and the cleaning period between the weeks was 4 days. The commercial tandospirone citrate tablets are taken three times on the first day of each cycle, with an interval of 5 hours, 10 mg each time; 30 mg of the preparation of the present invention is taken on the second day of each cycle. On the first day of each cycle, the subjects were before the first dose (0h) and after 0.25h, 0.5h, 1h, 1.5h, 2h, 5h, 5.25h, 5.5h, 6h, 6.5h, 7h, 8h, 3mL of venous blood was collected at 10h, 10.25h, 10.5h, 11h, 11.5h, 12h, 13h, and 16h, respectively, for a total of 21 blood collection points.
每周期第2天受试者于给药前(0h)及给药后0.5h、1h、1.5h、2h、2.5h、3h、3.5h、4h、4.5h、5h、5.5h、6h、8h、10h、12h、14h、16h、24h分别采集静脉血3mL，共19个采血点。计算相关的药代动力学参数，结果见表12。Subjects on the second day of each cycle before administration (0h) and after administration 0.5h, 1h, 1.5h, 2h, 2.5h, 3h, 3.5h, 4h, 4.5h, 5h, 5.5h, 6h, 8h 3mL of venous blood was collected at 10h, 12h, 14h, 16h, and 24h respectively, with a total of 19 blood sampling points. The relevant pharmacokinetic parameters were calculated, and the results are shown in Table 12.
表12人体药代动力学试验结果Table 12 Human pharmacokinetic test results
表12结果表明，与市售枸橼酸坦度螺酮片相比，本发明坦度螺酮药物组合物有效延迟了药物的达峰时间(T
max)，提高了生物利用度(AUC
0-24)，达到了药物持久平缓释放的目的。
The results in Table 12 show that, compared with the commercially available tandospirone citrate tablets, the tandospirone pharmaceutical composition of the present invention effectively delays the peak time (T max ) of the drug and improves the bioavailability (AUC 0- 24 ), to achieve the purpose of long-lasting and gentle release of the drug.
以上详细描述了本发明的优选实施方式，但是，本发明并不限于上述实施方式中的具体细节，在本发明的技术构思范围内，可以对本发明的技术方案进行多种简单变型，这些简单变型均属于本发明的保护范围。The preferred embodiments of the present invention are described in detail above. However, the present invention is not limited to the specific details in the above embodiments. Within the scope of the technical concept of the present invention, various simple modifications can be made to the technical solution of the present invention. These simple modifications All belong to the protection scope of the present invention.
Claims (10)
- 一种坦度螺酮药物组合物，其特征在于，包含药物活性成分、骨架材料、填充剂、助漂剂、润滑剂以及任选的粘合剂，所述药物活性成分为坦度螺酮、其药学上可接受的盐、或者坦度螺酮或其药学上可接受的盐的溶剂合物；A tandospirone pharmaceutical composition, which is characterized in that it comprises a pharmaceutical active ingredient, a framework material, a filler, a bleaching aid, a lubricant and an optional binder, and the pharmaceutical active ingredient is tanduspirone, A pharmaceutically acceptable salt thereof, or a solvate of tandospirone or a pharmaceutically acceptable salt thereof;所述骨架材料包括选自聚氧化乙烯WSR 303、聚氧化乙烯WSR 1105、聚氧化乙烯WSR 301、聚氧化乙烯WSR 205、聚氧化乙烯N-80中的一种或几种的组合；The framework material includes one or a combination of several selected from polyethylene oxide WSR 303, polyethylene oxide WSR 1105, polyethylene oxide WSR 301, polyethylene oxide WSR 205, and polyethylene oxide N-80;所述助漂剂选自碳酸钠、碳酸氢钠、碳酸氢钾、碳酸镁、碳酸钙中的一种或几种的组合；可选地，所述助漂剂选自碳酸钠和/或碳酸氢钠。The bleaching aid is selected from one or a combination of sodium carbonate, sodium bicarbonate, potassium bicarbonate, magnesium carbonate, and calcium carbonate; optionally, the bleaching aid is selected from sodium carbonate and/or carbonic acid Sodium hydrogen.
- 根据权利要求1所述的坦度螺酮药物组合物，其特征在于，所述坦度螺酮或其药学上可接受的盐的溶剂合物为其水合物的形式。The tandospirone pharmaceutical composition according to claim 1, wherein the solvate of tandospirone or a pharmaceutically acceptable salt thereof is in the form of a hydrate.
- 根据权利要求1所述的坦度螺酮药物组合物，其特征在于，所述坦度螺酮药物组合物中药物活性成分的含量为1-15％；The tandospirone pharmaceutical composition according to claim 1, wherein the content of active pharmaceutical ingredients in the tandospirone pharmaceutical composition is 1-15%;可选地，所述坦度螺酮药物组合物中药物活性成分的含量为2.5-10％，骨架材料的含量为5-75％，助漂剂的含量为1-20％；Optionally, the content of the pharmaceutical active ingredient in the tandospirone pharmaceutical composition is 2.5-10%, the content of the framework material is 5-75%, and the content of the bleaching aid is 1-20%;可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
- 根据权利要求1-3任一项所述的坦度螺酮药物组合物，其特征在于，所述药学上可接受的盐为盐酸盐、硫酸盐、酒石酸盐、草酸盐、马来酸盐、富马酸盐、枸橼酸盐、甲磺酸盐、对甲苯磺酸盐、硝酸盐；优选为盐酸盐或枸橼酸盐；更优选为枸橼酸盐。The tandospirone pharmaceutical composition according to any one of claims 1 to 3, wherein the pharmaceutically acceptable salt is hydrochloride, sulfate, tartrate, oxalate, maleic acid Salt, fumarate, citrate, methanesulfonate, p-toluenesulfonate, nitrate; preferably hydrochloride or citrate; more preferably citrate.
- 根据权利要求1-4任一项所述的坦度螺酮药物组合物，其特征在于，所述骨架材料还任选的包括羟丙基纤维素、羟乙基纤维素、羟丙基甲基纤维素、甲基纤维素、乙基纤维素、乙酸纤维素、交联聚乙烯吡咯烷酮、交联羧甲基纤维素钠中的一种或几种的组合；The tandospirone pharmaceutical composition according to any one of claims 1 to 4, wherein the framework material also optionally includes hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl One or a combination of cellulose, methyl cellulose, ethyl cellulose, cellulose acetate, cross-linked polyvinyl pyrrolidone, and cross-linked sodium carboxymethyl cellulose;可选地，所述羟丙基甲基纤维素选自HPMC E4M、HPMC E10M、HPMC K4M、HPMC K15M、HPMC K100M中的一种或几种的组合；Optionally, the hydroxypropyl methylcellulose is selected from one or a combination of HPMC E4M, HPMC E10M, HPMC K4M, HPMC K15M, HPMC K100M;可选地，所述羟丙基甲基纤维素选自HPMC K4M、HPMC K15M、HPMC K100M中的一种或几种的组合；Optionally, the hydroxypropyl methylcellulose is selected from one or a combination of HPMC K4M, HPMC K15M, HPMC K100M;可选地，所述骨架材料选自聚氧化乙烯WSR 303、聚氧化乙烯 WSR 1105、聚氧化乙烯WSR 301、聚氧化乙烯WSR 205、聚氧化乙烯N-80、HPMC K4M、HPMC K15M、羟乙基纤维素、羟丙基纤维素、交联聚乙烯吡咯烷酮中的一种或几种的组合；Optionally, the framework material is selected from polyethylene oxide WSR 303, polyethylene oxide WSR 1105, polyethylene oxide WSR 301, polyethylene oxide WSR 205, polyethylene oxide N-80, HPMC K4M, HPMC K15M, hydroxyethyl One or a combination of cellulose, hydroxypropyl cellulose, and cross-linked polyvinylpyrrolidone;可选地，所述粘合剂选自聚乙烯吡咯烷酮、明胶、黄原胶、糊精、聚乙烯醇、羧甲基纤维素中的一种或几种的组合；Optionally, the binder is selected from one or a combination of polyvinylpyrrolidone, gelatin, xanthan gum, dextrin, polyvinyl alcohol, and carboxymethyl cellulose;可选地，所述粘合剂选自聚乙烯吡咯烷酮和/或聚乙烯醇；Optionally, the adhesive is selected from polyvinylpyrrolidone and/or polyvinyl alcohol;可选地，所述填充剂选自乳糖、蔗糖、微晶纤维素、预胶化淀粉、甘露醇、山梨醇、木糖醇、葡萄糖、硫酸钙、磷酸氢钙、磷酸钙、氯化钙、氯化铝、氯化钠、氧化钙、氧化锌、氧化镁中的一种或几种的组合；Optionally, the filler is selected from lactose, sucrose, microcrystalline cellulose, pregelatinized starch, mannitol, sorbitol, xylitol, glucose, calcium sulfate, calcium hydrogen phosphate, calcium phosphate, calcium chloride, One or a combination of aluminum chloride, sodium chloride, calcium oxide, zinc oxide, and magnesium oxide;可选地，所述填充剂选自微晶纤维素；Optionally, the filler is selected from microcrystalline cellulose;可选地，所述的润滑剂选自滑石粉、微粉硅胶、硬脂酸镁、硬脂酸钙、硬脂酸锌、硬脂酸富马酸钠、十二烷基硫酸镁、十二烷基硫酸钠、氢化植物油中的一种或几种的组合；Optionally, the lubricant is selected from talc, micronized silica gel, magnesium stearate, calcium stearate, zinc stearate, sodium fumarate stearate, magnesium lauryl sulfate, dodecane One or a combination of sodium sulfate and hydrogenated vegetable oil;可选地，所述润滑剂选自硬脂酸镁。Optionally, the lubricant is selected from magnesium stearate.
- 根据权利要求1-5任一项所述的坦度螺酮药物组合物，其特征在于，所述坦度螺酮药物组合物包括如下重量百分比的组分：The tandospirone pharmaceutical composition according to any one of claims 1 to 5, wherein the tandospirone pharmaceutical composition comprises the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
可选地，所述坦度螺酮药物组合物包括如下重量百分比的组分：Optionally, the tandospirone pharmaceutical composition includes the following components in weight percentage:
- 根据权利要求1-6任一项所述的坦度螺酮药物组合物，其特征在于，所述坦度螺酮药物组合物的剂型选自片剂、丸剂或胶囊；可选为片剂。The tandospirone pharmaceutical composition according to any one of claims 1 to 6, wherein the dosage form of the tandospirone pharmaceutical composition is selected from the group consisting of tablets, pills or capsules; it can be a tablet.
- 权利要求1-7任一项所述的坦度螺酮药物组合物的制备方法，其特征在于，采用以下制备步骤：The preparation method of tandospirone pharmaceutical composition according to any one of claims 1-7, characterized in that the following preparation steps are adopted:a、将各组分分别过筛，取药物活性成分、骨架材料、粘合剂和填充剂，混合均匀；a. Sieving each component separately, take the active ingredient of the medicine, the skeleton material, the binder and the filler, and mix them evenly;b、加入助漂剂、润滑剂混合均匀，制成混合粉末，即得；b. Add bleaching aids and lubricants and mix evenly to make a mixed powder, ready to be obtained;可选地，将步骤b制得的混合粉末压片，制得片剂；可选地，所述压片的方式为粉末直接压片；Optionally, compress the mixed powder prepared in step b to obtain a tablet; optionally, the method of tableting is direct compression of the powder;或者，采用以下制备步骤：Or, use the following preparation steps:a、将药物活性成分、骨架材料、粘合剂和填充剂分别过筛，混合均匀，加入水制备软材，湿颗粒干燥，整粒过筛，制得干燥颗粒；a. Sieving the active ingredients of the medicine, the framework material, the binder and the filler separately, mixing them evenly, adding water to prepare the soft material, drying the wet granules, sieving the whole granules and sieving them to obtain dry granules;b、将助漂剂和润滑剂分别过筛，与步骤a中颗粒混合均匀，即得；b. Sieve the bleaching aid and lubricant separately, and mix them with the particles in step a to obtain;可选地，将步骤b中制得的颗粒进行压片，制得片剂。Optionally, the granules obtained in step b are compressed to obtain tablets.
- 根据权利要求8所述的坦度螺酮药物组合物的制备方法，其特征在于，采用以下制备步骤：The preparation method of tandospirone pharmaceutical composition according to claim 8, characterized in that the following preparation steps are adopted:a、将各组分分别过20～60目筛，取药物活性成分、骨架材料、粘合剂和填充剂，混合10～30分钟；a. Pass each component through a 20-60 mesh sieve, take the active ingredient of the medicine, the skeleton material, the binder and the filler, and mix for 10-30 minutes;b、再依次加入助漂剂、润滑剂混合3～10分钟，制成混合粉末，即得；b. Add bleaching aids and lubricants in sequence and mix for 3-10 minutes to make a mixed powder, ready to be obtained;可选地，使用16.4mm×7.9mm的冲头将步骤b中制得的混合粉末压片，制得片剂；可选地，所述压片的方式为粉末直接压片；Optionally, use a 16.4mm×7.9mm punch to tablet the mixed powder prepared in step b to obtain a tablet; optionally, the tableting method is direct compression of the powder;或者，采用以下制备步骤：Or, use the following preparation steps:a、将药物活性成分、骨架材料、粘合剂和填充剂分别过20～60目筛，混合5～30分钟，加入水制备软材，湿颗粒在35～70℃、20～50cfm条件下干燥5～30分钟，整粒过20～60目筛，制得干燥颗粒；a. Pass the active ingredients of the medicine, the skeleton material, the binder and the filler through a 20-60 mesh sieve, mix for 5-30 minutes, add water to prepare a soft material, and dry the wet granules at 35-70℃ and 20-50cfm. After 5-30 minutes, the whole granules are passed through a 20-60 mesh sieve to obtain dry granules;b、将助漂剂和润滑剂分别过20～60目筛，与步骤a中制得的干燥颗粒混合3～10分钟，即得；b. Pass the bleaching aid and lubricant through a 20-60 mesh sieve, and mix them with the dry granules obtained in step a for 3-10 minutes, to obtain;可选地，使用16.4mm×7.9mm的冲头将步骤b中制得的颗粒进行压片，制得片剂。Optionally, a 16.4mm×7.9mm punch is used to compress the granules obtained in step b to obtain tablets.
- 权利要求1-7任一项所述的坦度螺酮药物组合物在制备治疗中枢神经系统疾病和/或眼部疾病的药物中的用途；Use of the tandospirone pharmaceutical composition of any one of claims 1-7 in the preparation of a medicament for the treatment of central nervous system diseases and/or ocular diseases;可选地，所述中枢神经系统疾病包括焦虑症、抑郁症、失眠症、精神分裂、增龄性记忆障碍、神经衰弱、老年痴呆；Optionally, the central nervous system disease includes anxiety, depression, insomnia, schizophrenia, age-related memory disorders, neurasthenia, and Alzheimer's;可选地，所述眼部疾病包括青光眼、糖尿病性视网膜病、年龄相关性黄斑变性、视网膜水肿。Optionally, the ocular diseases include glaucoma, diabetic retinopathy, age-related macular degeneration, and retinal edema.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022531069A JP2023504409A (en) | 2019-12-25 | 2020-12-03 | Tandospirone pharmaceutical composition and its production method and use |
| KR1020227012970A KR20220066126A (en) | 2019-12-25 | 2020-12-03 | Tandospiron pharmaceutical composition and its manufacturing method and use |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911356537.0 | 2019-12-25 | ||
| CN201911356537.0A CN113018271B (en) | 2019-12-25 | 2019-12-25 | Tandospirone pharmaceutical composition and preparation method and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| WO2021129340A1 true WO2021129340A1 (en) | 2021-07-01 |
Family
ID=76458184
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CN2020/133624 WO2021129340A1 (en) | 2019-12-25 | 2020-12-03 | Tandospirone pharmaceutical composition, preparation method therefor and use thereof |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2023504409A (en) |
| KR (1) | KR20220066126A (en) |
| CN (1) | CN113018271B (en) |
| WO (1) | WO2021129340A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113440491A (en) * | 2021-08-17 | 2021-09-28 | 江苏百奥信康医药科技有限公司 | Tandospirone controlled-release orally disintegrating tablet and preparation method thereof |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002020291A (en) * | 2000-06-30 | 2002-01-23 | Sumitomo Pharmaceut Co Ltd | Therapeutic agent for cognitive dysfunction |
| WO2010065730A2 (en) * | 2008-12-05 | 2010-06-10 | Alcon Research, Ltd. | Pharmaceutical suspension |
| JP2013023459A (en) * | 2011-07-19 | 2013-02-04 | Dainippon Sumitomo Pharma Co Ltd | Mental disease therapeutic agent |
| CN103191432A (en) * | 2013-04-27 | 2013-07-10 | 中国药科大学 | Water-soluble medicine framework sustained release tablet and preparation method thereof |
| CN106344519A (en) * | 2015-07-17 | 2017-01-25 | 四川科瑞德制药股份有限公司 | Tandospirone enteric-coated mini-pill, and preparation method and application thereof |
| CN106397412A (en) * | 2015-07-30 | 2017-02-15 | 四川科瑞德制药股份有限公司 | 5-hydroxytryptamine receptor agonists, a preparing method thereof and uses of the receptor agonists |
| CN106619481A (en) * | 2015-10-30 | 2017-05-10 | 四川科瑞德制药股份有限公司 | Long-acting 5-HT1A receptor stimulant and preparation method thereof |
| CN106963766A (en) * | 2016-01-13 | 2017-07-21 | 四川科瑞德制药股份有限公司 | A kind of azaspiro ketone pharmaceutical composition and preparation method thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5330762A (en) * | 1992-02-27 | 1994-07-19 | Alza Corporation | Tandospiaine antidepressive therapy |
| AU2001246861A1 (en) * | 2000-04-10 | 2001-10-23 | Sumitomo Pharmaceuticals Co. Ltd. | Sustained release preparations |
| WO2010020098A1 (en) * | 2008-08-18 | 2010-02-25 | 北京天衡药物研究院 | Gastric retention drug delivery system, preparation method and use thereof |
| US20160022621A1 (en) * | 2013-03-12 | 2016-01-28 | Biohit Oyj | Composition for oral administration for binding aldehydes in the gastrointestinal tract |
| MX2018011278A (en) * | 2016-03-17 | 2019-07-08 | Thiogenesis Therapeutics Inc | Compositions for controlled release of cysteamine and systemic treatment of cysteamine sensitive disorders. |
-
2019
- 2019-12-25 CN CN201911356537.0A patent/CN113018271B/en active Active
-
2020
- 2020-12-03 KR KR1020227012970A patent/KR20220066126A/en unknown
- 2020-12-03 JP JP2022531069A patent/JP2023504409A/en active Pending
- 2020-12-03 WO PCT/CN2020/133624 patent/WO2021129340A1/en active Application Filing
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002020291A (en) * | 2000-06-30 | 2002-01-23 | Sumitomo Pharmaceut Co Ltd | Therapeutic agent for cognitive dysfunction |
| WO2010065730A2 (en) * | 2008-12-05 | 2010-06-10 | Alcon Research, Ltd. | Pharmaceutical suspension |
| JP2013023459A (en) * | 2011-07-19 | 2013-02-04 | Dainippon Sumitomo Pharma Co Ltd | Mental disease therapeutic agent |
| CN103191432A (en) * | 2013-04-27 | 2013-07-10 | 中国药科大学 | Water-soluble medicine framework sustained release tablet and preparation method thereof |
| CN106344519A (en) * | 2015-07-17 | 2017-01-25 | 四川科瑞德制药股份有限公司 | Tandospirone enteric-coated mini-pill, and preparation method and application thereof |
| CN106397412A (en) * | 2015-07-30 | 2017-02-15 | 四川科瑞德制药股份有限公司 | 5-hydroxytryptamine receptor agonists, a preparing method thereof and uses of the receptor agonists |
| CN106619481A (en) * | 2015-10-30 | 2017-05-10 | 四川科瑞德制药股份有限公司 | Long-acting 5-HT1A receptor stimulant and preparation method thereof |
| CN106963766A (en) * | 2016-01-13 | 2017-07-21 | 四川科瑞德制药股份有限公司 | A kind of azaspiro ketone pharmaceutical composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| TANG LEI, ZHANG WEN-BIN, TANG SHI-WEI, LIAO YAN, TU LI, HE QIN: "Investigation on the Preparation and the Factors Influencing the Drug Release Rate in Vitro of Osmotic Pump Tablet of Tandospirone Citrate", HUAXI YAOXUE ZAZHI - WEST CHINA JOURNAL OF PHARMACEUTICALSCIENCES, ZHONGGUO YAOXUEHUI, SICHUAN FENHUI, CHENGDU, CN, vol. 24, no. 3, 1 January 2009 (2009-01-01), CN, pages 232 - 234, XP055824288, ISSN: 1006-0103, DOI: 10.13375/j.cnki.wcjps.2009.03.039 * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023504409A (en) | 2023-02-03 |
| KR20220066126A (en) | 2022-05-23 |
| CN113018271B (en) | 2022-08-09 |
| CN113018271A (en) | 2021-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103751193B (en) | Include the medical composition and its use of BI 1356 and optional SGLT2 inhibitor | |
| CN102946869B (en) | The quick releasing formulation of gamma-hydroxybutyric acid and dosage form | |
| EP2470166B1 (en) | New compositions of 1-[2-(2,4-dimethyl-phenylsulfanyl)-phenyl]piperazine | |
| BRPI0708059A2 (en) | low flush niacin formulation | |
| WO2022193723A1 (en) | Composition, preparation method therefor, and use thereof | |
| CN109152740A (en) | The purposes in mostly dynamic obstacle (ADHD) that a kind of 5-(4-chlorophenyl)-2,5-dihydro-3H-imadazo[2,1-a is to release/extended release layered tablet and its in treatment attention missing/ | |
| WO2021129340A1 (en) | Tandospirone pharmaceutical composition, preparation method therefor and use thereof | |
| WO2021254409A1 (en) | Pharmaceutical composition of complex and preparation method therefor | |
| CN108514560B (en) | Lenalidomide stomach retention sustained-release tablet and preparation method thereof | |
| JP4866170B2 (en) | Hypnotic controlled release pharmaceutical composition and method for producing the same | |
| CN102008469A (en) | Method for preparing telmisartan amlodipine tablets | |
| US20230226049A1 (en) | Acalabrutinib maleate dosage forms | |
| KR101583452B1 (en) | A pharmaceutical composition for treating gastrointestinal diseases | |
| CN1172429A (en) | Sustained-release drug delivery employing powdered hydrocolloid gum obtainable from higher plants | |
| CN108969498B (en) | Tizanidine hydrochloride sustained release preparation, preparation process and application thereof | |
| CN101375852B (en) | Boletic acid quetiapine oral preparation and preparation method thereof | |
| WO2023173460A1 (en) | Pharmaceutical composition of sglt-2 inhibitor | |
| WO2021036230A1 (en) | Ranolazine sustained-release composition and preparation method therefor | |
| CN103432093B (en) | Pridinol methanesulfonate matrix sustained-release tablet and preparation method thereof | |
| CN1245980C (en) | Oral slow-release and controlled-release preparation for curing depression | |
| CN116615184A (en) | Oral solid preparation | |
| WO2023093640A1 (en) | Darolutamide pharmaceutical composition, preparation method therefor and use thereof | |
| Harish | Formulation and Evaluation of Bilayer Tablets: Glimepiride in Floating Drug Delivery and Metformin in Sustained Release | |
| CN111544404A (en) | Dolichocalcitol controlled-release tablet | |
| CN101129358A (en) | Moguisteine sustained-release tablet and method of preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20905761 Country of ref document: EP Kind code of ref document: A1 |
|
| ENP | Entry into the national phase |
Ref document number: 20227012970 Country of ref document: KR Kind code of ref document: A |
|
| ENP | Entry into the national phase |
Ref document number: 2022531069 Country of ref document: JP Kind code of ref document: A |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20905761 Country of ref document: EP Kind code of ref document: A1 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20905761 Country of ref document: EP Kind code of ref document: A1 |
|
| 32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM1205A DATED 23/01/2023) |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 20905761 Country of ref document: EP Kind code of ref document: A1 |